Sector News

Health Enterprise East sells spin out to Allergan

November 6, 2015
Life sciences

Health Enterprise East, a provider of business and innovation management services to the NHS and industry, has sold Northwood Medical Innovations to global pharma Allergan for an undisclosed amount.

Founded in 2010 as a spin out of HEE and West Hertfordshire Hospitals NHS Trust, Northwood has developed a minimally invasive pioneering implant technology, earFold, as an alternative to conventional surgery for correcting prominent ears.

The procedure takes just 20 minutes under local anaesthetic as an outpatient, compared to the traditional two hours in general surgery, and overall outcomes are improved with reduced risk of keloid scaring and cartilage damage, less chance of infection, faster recovery times and improved symmetry when both ears are being corrected, according to HEE.

Botox-maker Allergan, which is currently in talks with Pfizer over a potential merger, is intending to commercialise the product widely across Europe, and will continue to explore the regulatory pathways and necessary clinical data requirements for launching the medical device in other countries, including the US.

Revenues from the company’s sale “will be re-invested into ensuring that other pioneering innovations from staff across the NHS are identified, developed and commercialised,” said HEE.

Source: Pharma Times

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach